본문 바로가기 주메뉴 바로가기
PIPELINE

InnoCure is developing highly differentiated molecules for the treatment of cancer and rare diseases.

We have created a balanced portfolio of traditionally undruggable targets.

undruggable target
Modality Program Indication Discovery Lead Optimization IND Enabling Phase l
MILPROTAC
(Bivalent Degrader)
ICTP - 101 NSCLC, GC, Multiple
Bivalent Degrader
(PROTAC)
ICTP - 201 NUT midline carcinoma
ICTP - 301 Advanced solid tumor
ICTP - 401 Pancreatic cancer
Bivalent Degrader
(AUPTAC)
ICTP - 501 Multiple

ICT - 101

IndicationGC, NSCLC, Multiple

  • Discovery
  • IND Enabling
  • Phase l
  • Phase ll